4688美高梅集团(中国)股份有限公司

Company News

Zhende Establishes Strategic Partnership with ALLtest Biotechnology and Launches COVID-19 Antigen Test Kit

Zhende Health Technology Co., Ltd., a wholly-owned subsidiary of Zhende Healthcare Products Co., Ltd. and Hangzhou ALLtest Biotechnology Co., Ltd. (hereinafter referred to as “ALL test Biotechnology”) entered into a strategic cooperation agreement in Shaoxing on April 12, 2022. Both parties shall cooperate on COVID-19 antigen test kits to help contain the epidemic.


Join Hands in Fighting the Epidemic


In the No. 21 (2022) Announcement on the (trial) Plan for the Application of COVID-19 Antigen Test, the Joint Prevention and Control Mechanism of the State Council of China decided to complement nucleic acid detection with antigen detection for more rapid detection of COVID-19 infection.

微信图片_20220414093128.jpg

▲Manual Nucleic Acid Extraction was Mostly Used in the Past

ALL test Biotechnology leverages strengths in R & D and innovation to provide high-quality COVID-19 antigen test kits while ensuring high production capacity. Zhende takes charge of sales of antigen test kits and other services on online and offline platforms throughout China. Both parties work closely to promote COVID-19 antigen test kits and contribute to epidemic prevention and control. 

微信图片_20220414093137.jpg

▲ Chairman Lu Jianguo of Zhende and Chairman Gao Fei of ALL test Biotechnology 

are Signing the Agreement


“It has been three years since the COVID-19 pandemic broke out. Antigen detection is a new measure taken by China to contain the outbreak. It helps lower cost and reduce pressure on mass screening and testing resources. Over the past three years, Zhende has been actively engaged in epidemic prevention and control. By working with ALL test Biotechnology, both parties can rely on the strengths of ALLtest Biotechnology in R & D and innovation and the extensive service network of Zhende to deliver high-quality products to the frontline of epidemic prevention and control in China and further contribute to the implementation of the dynamic zero COVID-19 strategy,” said Li Jianguo, Chairman of Zhende, at the signing ceremony. 


微信图片_20220414093141.jpg

▲ Chairman Lu Delivered an Address at the Signing Ceremony


“The win-win cooperation between Zhende and ALL test Biotechnology creates a lot of opportunities for both parties. ALL test Biotechnology specializes in R&D, production and sales of IVD reagents and has the capacity to produce COVID-19 antigen test kits. Working together with Zhende, which boasts an extensive business network across China, multiple logistics channels and professional services, both parties can bring into play the strengths of each other to shoulder greater responsibilities and contribute more to epidemic prevention and control,” said Chairman Gao. 


微信图片_20220414093144.jpg

▲Chairman Lu Delivered an Address at the Signing Ceremony


COVID-19 Antigen Test Kits


The 2019-nCoV antigen detection kit (latex immunochromatography) is able to detect N and S protein simultaneously through dual-target detection, which can maximize positive detection while ensuring specificity and avoid false negatives caused by mutations in a single proteinCOVID-19 Antigen Test Kits.

微信图片_20220414093148.jpg

微信图片_20220414093159.jpg

▲ COVID-19 Antigen Test Kit of Zhende

The COVID-19 Antigen Test Kit of Zhende is easy to use and is a convenient choice for different people in different application scenarios. It also features rapid detection and produces results in 15 minutes.


The partnership between ALL test Biotechnology and Zhende will not only be focused on COVID-19 antigen test kit. In the future, both parties will deepen cooperation in other projects, explore new ways of cooperation in home use IVD products and help the customers of both parties grow more rapidly in the Chinese market.